Aarti Drugs Limited Market Cap ($460.26 Million)
Market Cap & Net Worth: Aarti Drugs Limited (AARTIDRUGS)
Aarti Drugs Limited market cap. Aarti Drugs Limited (NSE:AARTIDRUGS) has a market capitalization of $460.26 Million (Rs42.56 Billion) as of November 4, 2026. Listed on the NSE stock exchange, this India-based company holds position #12323 globally and #612 in its home market, demonstrating a 22.92% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aarti Drugs Limited's stock price Rs466.30 by its total outstanding shares 91270000 (91.27 Million). Also see AARTIDRUGS cash generation efficiency for how efficiently the company converts equity into cash flow.
Aarti Drugs Limited Market Cap History (2015–2026)
Aarti Drugs Limited market cap history from 2015 to 2026. Data shows growth from $141.74 Million to $460.26 Million (11.17% CAGR). Check today's stock price for Aarti Drugs Limited for real-time trading data and today's change.
Index Memberships
Aarti Drugs Limited is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY MIDSMALLCAP 400
NIFTYMIDSML400
|
$1.09 Trillion | 0.04% | #297 of 400 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$3.10 Trillion | 0.01% | #467 of 750 |
Weight: Aarti Drugs Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Aarti Drugs Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aarti Drugs Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Aarti Drugs Limited (AARTIDRUGS) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.02x
Aarti Drugs Limited's market cap is 0.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.24x
Aarti Drugs Limited's market cap is 0.24 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $154.43 Million | $11.95 Billion | $805.63 Million | 0.01x | 0.19x |
| 2018 | $140.13 Million | $12.44 Billion | $823.07 Million | 0.01x | 0.17x |
| 2019 | $141.06 Million | $15.61 Billion | $897.51 Million | 0.01x | 0.16x |
| 2020 | $691.59 Million | $18.06 Billion | $1.41 Billion | 0.04x | 0.49x |
| 2021 | $534.42 Million | $21.55 Billion | $2.80 Billion | 0.02x | 0.19x |
| 2022 | $452.12 Million | $24.89 Billion | $2.05 Billion | 0.02x | 0.22x |
| 2023 | $481.94 Million | $27.16 Billion | $1.66 Billion | 0.02x | 0.29x |
| 2024 | $454.44 Million | $25.29 Billion | $1.71 Billion | 0.02x | 0.27x |
| 2025 | $406.32 Million | $23.87 Billion | $1.68 Billion | 0.02x | 0.24x |
| 2026 | $460.26 Million | $25.65 Billion | $1.95 Billion | 0.02x | 0.24x |
Competitor Companies of AARTIDRUGS by Market Capitalization
Companies near Aarti Drugs Limited in the global market cap rankings as of November 4, 2026. Also see total assets of Aarti Drugs Limited for a full breakdown of the balance sheet.
Key companies related to Aarti Drugs Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #509 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #534 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #580 globally with a market cap of $46.03 Billion USD ( CN¥314.55 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #509 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #534 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $45.90 |
| #580 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $46.03 Billion | CN¥49.31 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Aarti Drugs Limited (2015–2026)
Market capitalization of Aarti Drugs Limited from 2015 to today. Between 2015 and today, Aarti Drugs Limited's market cap moved from $141.74 Million to $ 460.26 Million, with a yearly change of 11.17%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs460.26 Million | +13.28% |
| 2025 | Rs406.32 Million | -10.59% |
| 2024 | Rs454.44 Million | -5.71% |
| 2023 | Rs481.94 Million | +6.60% |
| 2022 | Rs452.12 Million | -15.40% |
| 2021 | Rs534.42 Million | -22.73% |
| 2020 | Rs691.59 Million | +390.28% |
| 2019 | Rs141.06 Million | +0.67% |
| 2018 | Rs140.13 Million | -9.26% |
| 2017 | Rs154.43 Million | +6.07% |
| 2016 | Rs145.58 Million | +2.71% |
| 2015 | Rs141.74 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Aarti Drugs Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $460.26 Million USD |
| MoneyControl | $460.26 Million USD |
| MarketWatch | $460.26 Million USD |
| marketcap.company | $460.26 Million USD |
| Reuters | $460.26 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Aarti Drugs Limited
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enro… Read more